Search PubMed⌕ Search

Biomedical subjects

H D Flad

Publications and source records attributed to H D Flad.

At least 109 records · Page 6Linked to original sources
PubMed1994

On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells.

Previously we had shown that, upon activation with viable bacillus Calmette-Guérin (BCG), peripheral blood mononuclear cells (PBMNC) could be rendered cytotoxic against otherwise insensitive natural killer (NK)-resistant bladder cancer cell lines. This phenomenon had been termed the BCG-activated killer (BAK) cell phenomenon. By means of depletion and enrichment procedures of mononuclear cell subpopulations derived from BCG-activated PBMNC we further characterized the cytolytic BAK effector cells functionally in an in vitro cytotoxicity assay against the bladder carcinoma cell line BT-A and phenotypically in their pathway of activation. Neither macrophages nor CD4+ T-helper/inducer cells exerted cytotoxic BAK activity. This cytotoxicity was restricted to the CD8+CD56+ subpopulation of T-cytotoxic/NK cells. Furthermore, activation of BAK cells via interferon gamma (IFN-gamma) was evidenced by the complete inhibition of BAK cell generation with an IFN-gamma antibody.

Administration, Intravesical↗
PubMed1994

Detection of intracellular interleukin 2: evidence for novel immunologically related forms of the lymphokine.

At present, few data are available on intracellular interleukin 2 (IL-2) and its posttranscriptional regulation. Unlike other lymphokines, IL-2 does not accumulate within the cell, but is rapidly secreted following its production. The process of detection and biochemical characterization of intracellular IL-2 involved using a high producer subclone of the Jurkat T-lymphoma line as a source for IL-2, in combination with a two-step separation protocol and a sensitive detection method. Following phytohemagglutinin (PHA)/4 beta-phorbol 12-myristate 13 acetate (TPA) stimulation, a 14 kDa molecule could be visualized in Western blots by means of two monoclonal anti-IL-2 antibodies possessing different epitope specificities. This molecule exhibited biological activity of IL-2 as determined by a murine cytotoxic T-cell proliferation assay. In addition to this biologically active form of the lymphokine, a strongly immunoreactive protein with a molecular weight of 54 kDa (P54) was found in Jurkat cell lysates. Further biochemical characterization of this intracellular variant revealed an isoelectric point similar to that of secreted forms of IL-2. All attempts to split the 54 kDa molecule into smaller subunits failed, and no biological IL-2 activity could be measured in response to P54. However, the appearance of this high molecular weight variant followed clear-cut time kinetics. The highest concentration of P54 was found to occur after 2 h of stimulation. Thereafter its concentration decreased continuously, while the amount of the biologically active 14 kDa variant increased under ongoing stimulation. One possible explanation for these results is that P54 may represent an immature form of IL-2 that is tightly linked to a carrier molecule.

Extracellular Space↗
PubMed1994

Transforming growth factor-beta 1 (TGF-beta 1) inhibits DNA synthesis of PWM-stimulated PBMC via suppression of IL-2 and IL-6 production.

The multifunctional cytokine transforming growth factor-beta 1 (TGF-beta 1) is known to inhibit the proliferation of lymphocytes. However, the role of TGF-beta 1 in the production and secretion of various interleukins is not yet clear. In this study we have analysed in parallel the effects of TGF-beta 1 on both DNA synthesis and production of the cytokines IL-1, IL-2, IL-6, and TNF-alpha by pokeweed mitogen-stimulated peripheral blood mononuclear cells. With this stimulation system we show that TGF-beta 1 at a concentration of 15 ng/ml significantly suppresses IL-2 and IL-6 production. The release of IL-1 and TNF-alpha, however, was not influenced under these conditions. Under similar conditions DNA synthesis of PWM-stimulated PBMC was found to be inhibited by 50 +/- 10%. Using flow cytometric methods we could demonstrate that TGF-beta 1 arrested the cells in the G0/G1 phase of the cell cycle. Taken together, these results suggest that TGF-beta 1 may suppress immune responses by inhibiting the endogenous production of IL-2 and IL-6.

DNA↗
PubMed1994

Detection of Mycobacterium leprae by three-primer PCR.

Recently, polymerase chain reaction has been introduced for the species-specific assessment of Mycobacterium leprae (1). To avoid Southern blotting techniques using radioactively labelled oligonucleotide probes, the aim of this study was to establish a three primer-based single-step PCR technique. Using primers designed for this purpose we amplified a part of the gene encoding for the 16S ribosomal RNA of slowly growing mycobacteria. Due to the species-specific antisense primer a second, smaller fragment specific for M. leprae was amplified. Our results show that the employment of a second antisense primer in the PCR may be a substitution for Southern blot hybridization.

Base Sequence↗
PubMed1994

Mycobacterium leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy (MDT).

Skin biopsies from untreated and MDT-treated patients were examined for infiltrating cells and cells producing the cytokines TNF-alpha, IFN-gamma, and IL-1 beta using immunohistochemistry. Biopsy specimens from untreated tuberculoid leprosy patients were characterized by the presence of cells producing TNF-alpha, IFN-gamma, and IL-1 beta and of subepidermal Langerhans cells. These cells were rarely found or completely absent in biopsies of untreated lepromatous leprosy patients, but tended to increase under MDT. In a short-term therapy trial for three months with brodimoprim, dapsone, and rifampicin, 12 patients were monitored by follow-up biopsies. Semiquantitative PCR for mycobacterial DNA revealed two groups of patients: one group in which mycobacterial DNA in follow-up biopsies remained constant and a second group in which a decrease of mycobacterial DNA during therapy was noted. Immunophenotyping in these follow-up biopsies revealed that in the latter group IFN-gamma-positive cells and Langerhans cells were present and gamma delta T cell receptor-positive cells tended to decrease during therapy. In contrast, in patients whose mycobacterial DNA did not change during therapy, these phenotypical manifestations were not observed. We therefore, conclude that assessment of mycobacterial DNA in combination with phenotyping of infiltrating cells and determination of cytokine patterns may be useful tools in establishing criteria for the effectiveness and duration of MDT in patients with leprosy.

Anti-Bacterial Agents↗
PubMed1994

Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures.

We have investigated the interaction of soluble peptidoglycan (sPG), in comparison with lipopolysaccharide (LPS), with human mononuclear cells (MNC) by determining the capacity of sPG to induce interleukin-6 (IL-6) and IL-1 release. In addition, we investigated the modulation of their interaction by anti-CD14 monoclonal antibody and by partial structures of LPS. We found that sPG, like LPS, was able to induce IL-6 and IL-1 production by MNC. However, dose-response experiments revealed that at least 3,000 ng of sPG per ml was necessary for induction, whereas the optimal LPS concentration was 1 ng/ml. Anti-CD14 monoclonal antibody reduced sPG- and LPS-induced IL-6 and IL-1 production. Moreover, partial structures of LPS were able to reduce monokine production induced by sPG and LPS. We conclude that sPG constitutes, like LPS, an inflammatory cytokine inducer and that CD14 is involved in the activation of human monocytes not only by LPS but also by sPG.

Acute-Phase Proteins↗
PubMed1994

Altered antigen-presenting capacity of human monocytes after phagocytosis of bacteria.

The antigen-presenting and accessory functions of monocytes were studied after phagocytosis of bacteria. Peripheral blood monocytes isolated from mononuclear cells by counterflow elutriation were incubated with suspensions of opsonized bacteria (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, or Salmonella enteritidis) under conditions in which at least 80% of the monocytes engulfed microorganisms. Either the cells were pulsed with antigen (purified derivative of tuberculin or tetanus toxoid) and used as antigen-presenting cells for autologous T lymphocytes or the accessory function of the cells was examined in pokeweed mitogen-activated cultures of T cells. It has been found that phagocytosis of bacteria by monocytes reduces their ability to trigger antigen- and mitogen-induced proliferation. The reduced proliferative response of T lymphocytes was not due to a change of the kinetics of the response or triggering of suppressor mechanisms. Furthermore, antigen processing was not affected much after phagocytosis of bacteria since antigen-pulsed and paraformaldehyde-fixed cells containing bacteria were comparable to control cells in their antigen-presenting capacity. This phenomenon was observed after phagocytosis of both living and dead bacteria and was not correlated to the viability of monocytes, which were more affected after phagocytosis of living bacteria than of dead ones. As a result of phagocytosis of bacteria, reduced expression of CD54, CD14, and HLA-DQ, variable reduction of HLA-DP, CD58, and CD64, and reduced viability of monocytes were observed. In conclusion, phagocytosis of bacteria by monocytes affects their antigen-presenting and accessory functions presumably because of changes in the expression of molecules essential for monocyte-T-cell interactions and reduction of their viability.

Antigen Presentation↗
PubMed1994

Defective antigen presentation by Mycobacterium tuberculosis-infected monocytes.

In this study we investigated the effect of an in vitro infection with Mycobacterium tuberculosis on the ability of human monocytes to present the soluble antigen tetanus toxoid to T cells. We observed that tetanus toxoid-specific T-cell proliferation was markedly reduced when monocytes were infected with large numbers (bacterium-to-monocyte ratio, 50:1) of both viable and heat-killed mycobacteria. The level of antigen-induced gamma interferon release also was decreased when M. tuberculosis-containing monocytes were used as antigen-presenting cells. However, mycobacterium-infected monocytes did not show or trigger suppressive activity, because the presence of mycobacterium-infected monocytes did not affect the T-cell response induced by tetanus toxoid-pulsed control monocytes. When M. tuberculosis-infected monocytes were fixed with paraformaldehyde, they were not able to serve as antigen-presenting cells even in the presence of untreated accessory monocytes. Moreover, the uptake of both viable and heat-killed M. tuberculosis cells reduced the expression of human leukocyte antigen DR on monocytes. With regard to accessory function, monocytes infected with large numbers of mycobacteria were less efficient as accessory cells than were control monocytes in cultures of T cells activated with pokeweed mitogen. These results indicate that infection with large numbers of M. tuberculosis cells impairs the ability of monocytes to process and/or present soluble antigen and to serve as accessory cells in T-cell activation.

Antigen Presentation↗
PubMed1994

Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein).

AIMS--To elucidate the fine specificities of the antibodies MIB 1 and MIB 3 and of additional monoclonal antibodies which also recognise the Ki-67 protein (MIB 5, IND.64, JG-67-2a). METHODS--Different parts of the Ki-67 protein cDNA were expressed in Escherichia coli. Bacterial lysates were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted on to nitrocellulose. Additionally different peptides were synthesised on a membrane support (SPOT-Blot). The immunoreactivity of the antibodies with the recombinant proteins and the immobilised synthetic peptides, respectively, was analysed. A competition enzyme linked immunosorbent assay (ELISA) using a soluble synthetic peptide was also performed. RESULTS--The epitopes of all antibodies tested were contained within the same region of seven amino acids. The antibodies MIB 1 and MIB 3 required the five amino acid sequence FKELF for binding, whereas Ki-67, JG-67-2a, MIB 5 and IND.64 detected the sequence FKEL. CONCLUSIONS--It is concluded that the amino acid sequence FKELF represents an immunodominant area of the Ki-67 protein and that there is no correlation between the ability to detect the Ki-67 protein in paraffin wax sections irradiated with microwaves and the epitopes recognised by the antibodies.

Amino Acid Sequence↗
PubMed1993

Phenotypical and functional characterization of Fc gamma receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity.

Fc gamma receptor I-positive (CD64+) and Fc gamma receptor I-negative (CD64-) monocytes were prepared from highly purified (elutriation-derived) human monocytes by cytofluorograph cell sorting, and a phenotypical and functional dissociation of the isolated CD64+ and CD64- monocyte subsets is demonstrated. Surface analyses revealed that the surface antigen pattern of CD64+ monocytes corresponds to the phenotype of typical unseparated monocytes. In contrast, CD64- monocytes are characterized by high expression of major histocompatibility complex (MHC) class I antigens (HLA-A, -B, -C) and MHC class II antigens (HLA-DR, -DP, -DQ), and low expression of the monocyte-specific marker CD14 which is found on nearly all CD64+ monocytes. However, 75% of the CD64- cells were found to be esterase-positive, and 85% were positive for the the CD64- cells were found to be esterase-positive, and 85% were positive for the monocyte/macrophage-specific intracellular antigen CD68. Furthermore, CD64- monocytes show significantly higher expression of CD45RA and Fc gamma receptor III (CD16) than CD64+ monocytes, but lack the natural killer cell markers CD56 and CD57. Functional studies showed that cells of the minor CD64- monocyte subset have a higher accessory cell capacity in antigen-driven T cell activation than CD64+ monocytes. CD64- monocytes pretreated with PPD (purified protein derivative of tuberculin) induced up to tentimes more interferon-gamma and also higher proliferation in responding autologous T cells than PPD-pretreated CD64+ monocytes. Similar results were obtained for T cells in mixed leukocyte reaction. Interferon-gamma release and proliferation of allogeneic lymphocytes were consistently higher in the presence of irradiated CD64- monocytes than of irradiated CD64+ monocytes. Furthermore, when CD64- and CD64+ monocytes were stimulated with Newcastle disease virus, we measured an up to 67-fold higher interferon-alpha release from CD64- than from CD64+ monocytes, indicating a higher anti-viral capacity of this subset. CD64- monocytes showed lower activity in the phagocytosis of unopsonized particles and also lower zymosan- or latex-induced chemiluminescence than CD64+ monocytes. These findings indicate that CD64- monocytes, although comprising only less than 10% of all peripheral blood monocytes, represent a monocyte subpopulation efficiently interacting in vitro with T cells and, additionally, are the major source of interferon-alpha.

Antigen-Presenting Cells↗
PubMed1993

Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.

Cytotoxicity against two human bladder carcinoma cell lines (BT-A and BT-B) was investigated using human peripheral blood mononuclear cells (PBMC) stimulated with viable bacillus Calmette-Guérin (BCG) or sonicated BCG (s-BCG). We applied a cytotoxicity assay based on radioactive labelling of tumour cells by incorporation of L[3H]methionine. The results were compared with the cytotoxicity exerted by lymphokine-activated killer (LAK) cells generated by interleukin-2 (IL-2) and interferon gamma (IFN gamma). BCG-stimulated PBMC showed a cytotoxic potential against BT-A and BT-B comparable to that of IFN gamma-generated LAK cells, but this did not reach the level of IL-2-generated LAK cells. We termed these cytotoxic effectors BCG-activated killer (BAK) cells. In contrast to their cytotoxicity against bladder tumour cells, BAK cells did not differ from unstimulated PBMC in the killing of K562 cells. Only viable but not sonicated BCG was able to induce cytotoxicity against BT-A and BT-B. We could demonstrate the presence of the cytokines IFN gamma, IL-2, tumour necrosis factor alpha (TNF alpha) and TNF beta in the supernatants harvested during the generation of BAK cells. Monoclonal antibodies neutralizing IFN gamma were able to inhibit BCG-mediated cytotoxicity, giving evidence of the involvement of IFN gamma in the induction of BAK cells. Furthermore, we performed experiments to investigate the cytotoxic potential of distinct cell populations. The cells effective in BCG-activated killing of bladder tumour cells could be localized within the CD8+/CD56+ lymphocyte subset. CD4+ cells and macrophages did not exhibit cytolytic activity. Our findings imply that the activation by BCG of CD8+/CD56+ killer cells might be an important antitumoral mechanism during BCG therapy against superficial urothelial bladder cancer.

BCG Vaccine↗
PubMed1993

A novel molecular variant of the neutrophil-activating peptide NAP-2 with enhanced biological activity is truncated at the C-terminus: identification by antibodies with defined epitope specificity.

The human neutrophil-activating peptide 2 (NAP-2) belongs to the so-called beta-thromboglobulin/interleukin 8-family of chemotactic and reparative host defense cytokines. NAP-2 represents one of several N-terminally truncated cleavage products that originate from platelet-derived precursor molecules through proteolytic processing. Among these homologous isoforms that are comprised as beta-thromboglobulin antigen (beta-TG Ag), NAP-2 is recognized as the major component, having the highest potential for the activation of polymorphonuclear neutrophils (PMN). We now present evidence that there exists a second molecular form of NAP-2 with even higher biological activity. This novel isoform was detected in concentrates of culture supernatants from peripheral blood mononuclear cells, and could be separated from authentic NAP-2 by several steps of column chromatography. It had an N-terminus identical to that of NAP-2 but was biochemically different as indicated by its slightly lower molecular weight and a higher isoelectric point. To examine our hypothesis that the polypeptide represented a C-terminally truncated variant of NAP-2, we prepared synthetic peptides that were used for the induction and characterization of two rabbit antibody fractions, directed against different and defined epitopes within the C-terminal alpha-helix of the NAP-2 molecule. Comparison of reactivity patterns of these antibodies in Western blots as well as in a NAP-2 biological assay (PMN degranulation assay) confirmed that the variant NAP-2 was truncated at its C-terminus by at least one and by maximally three residues. The specific activity of the truncated polypeptide was estimated to be about four-fold higher than that of authentic NAP-2, as determined in the PMN degranulation assay. Thus, proteolytic modification at the C-terminus appears to play a role in the regulation of NAP-2-biological activity.

Amino Acid Sequence↗
PubMed1993

Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.

Several immunobiological effects of intravesical bacillus Calmette-Guérin (BCG) during immunotherapy of superficial bladder cancer have been suggested as possible mediators of the mode of action. In an attempt to elucidate which of these effects is relevant to tumoricidal activity, an in vitro cytotoxicity assay was employed in which the direct effects of BCG and of cytokines against four transitional carcinoma cell lines were studied. Furthermore, peripheral blood mononuclear cells (PBMNC) were analyzed for their cytotoxic potential against these target cells. We found that none of the cytokines interleukin-1, interleukin-2, interferon-gamma, tumor necrosis factor alpha, lymphotoxin, or BCG alone were cytotoxic against the bladder carcinoma cell lines. However, a pronounced cytotoxicity against these targets resistant to natural killer cells could be induced in PBMNC by coincubation with viable BCG. We termed this the BCG-activated killer (BAK) cell phenomenon. In contrast to lymphokine-activated (LAK) cells, these BAK cells needed prolonged activation for 7 days and did not enhance the cytotoxicity against K562 target cells sensitive to natural killer cells. Nonviable, heat-inactivated BCG was significantly less effective, and sonificated fractions of BCG were not effective in stimulating PBMNC towards BAK cell activity. In vitro dissection of effects observed during BCG intravesical therapy may give more insight into the mode of action of BCG and may help to separate primary tumoricidal effector mechanisms from secondary concomitant phenomena. Further characterization of the BAK cell may result in an improvement of intravesical BCG immunotherapy.

BCG Vaccine↗
PubMed1993

Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production.

In the present report, we describe that synthetic inhibitors of and polyclonal and monoclonal antibodies against the membrane ectoenzyme dipeptidyl peptidase IV (DP IV, CD26) inhibit the production of IL-2 and IL-6 and, concomitantly, DNA synthesis of pokeweed mitogen-stimulated peripheral blood mononuclear cells (PBMC). The release of IL-1 and TNF-alpha, was not influenced under these conditions. The data support the hypothesis that DP IV, possibly in conjunction with other peptidase, is involved in the regulation of activation and proliferation of T lymphocytes.

Antibodies, Monoclonal↗
PubMed1993

Agonists and antagonists for lipopolysaccharide-induced cytokines.

Agonistic and antagonistic properties of LPS and partial structures in the induction of cytokines are reviewed. Studies on structure-activity relationships of LPS and lipid A with human mononuclear cells reveal that S- and notably R-form LPS are very potent cytokine inducers. Synthetic E. coli lipid A is somewhat less active, whereas synthetic S. minnesota-type lipid A is significantly less active. Pentaacylated forms of lipid A are less potent than hexaacylated forms, and tetraacylated synthetic precursor Ia and bisacylated disaccharides and monosaccharides are completely inactive, indicating that a structure-dependent hierarchy of LPS and lipid A partial structures determines the monokine-inducing capacity in human mononuclear cells. Precursor Ia is a potent LPS antagonist. The mechanism of its inhibitory activity is shown to be due to competitive binding to cellular binding sites (receptors). Proinflammatory and antiinflammatory cytokines, receptor antagonists, and soluble cytokine receptors influence the cytokine-inducing activity of LPS, suggesting a complex regulatory network.

Acute-Phase Reaction↗
PubMed1993

Anti-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1 phase of the cell cycle.

Three different anti-CD26 monoclonal antibodies (mAbs) are described, which specifically inhibited proliferation of human T lymphocytes after stimulation with PHA, tetanus toxoid or soluble anti-CD3 mAb. Anti-CD26 mAbs induced in T cells a dose-dependent shift of the maximum of DNA synthesis, which was due to a transitory arrest of cells in the cell cycle. This cell cycle arrest was found to occur in the late phase of G1 since the expression of the T cell activation markers CD25-, CD71-, and HLA-DR-positive cells was the same in anti-CD26 mAb-containing and control cultures. Propidium iodide staining further confirmed the assumption that the arrest occurs in the first round of the cell cycle before S phase cells were detectable. Because the cells were arrested before consuming IL-2 in the S phase, we observed in accumulation of IL-2 in anti-CD26 mAb-containing cultures, whereas IFN-gamma production by PHA-activated T lymphocytes was reduced. These data indicate that CD26 is involved in the processes of T cell activation and proliferation.

Antibodies, Monoclonal↗